Oligomers count

attyloid’s sFIDA® platform technology offers a cutting-edge approach for the quantitative detection of single oligomers and aggregates, which serve as biomarkers of CNS disorders such as Alzheimer’s Disease and Parkinson’s Disease.

sFIDA® technology

Aggregates under the spotlight

The sFIDA® platform integrates the precision of a selective immunoassay with the superior sensitivity of fluorescence microscopy to count single oligomers, aggregates, and particles. As a result, sFIDA® can detect these biomarkers at unprecedented levels of sensitivity and specificity.

Applications

CNS
biomarkers

  • MoA validation

  • Patient selection and stratification

  • Target engagement assaying

  • Drug efficacy testing

Subvisible particle analysis

  • R&D of biologicals

  • Cell culture screening

  • Formulation development

  • QC in bioproduction

Viral particle
analysis

  • Vaccine production

  • Protein expression

  • Viral therapeutics

  • Antiviral development

We are

attyloid is an academicy spin-off dedicated to the scientific rigor that the complex fields of protein misfolding and Central Nervous System (CNS) diseases demand. Our research plays a critical role in diagnosing and understanding these diseases and paving the way for innovative therapeutics.

Interested in our

cutting-edge technology?

sFIDA® in numbers

oligomer sizes

1.000 nm

sample volume

1.000 µl

detection limit

1.000 fM

dynamic range orders of magnitude

1 ​

Latest news

  • Attyloid at AAIC 2026 in London: Enhancing CNS biomarker strategies

    July 10, 2026

    How can biomarkers provide a more complete picture of neurodegenerative disease? We are ...

  • New Publication: Exploring the Potential and Limitations of Seeded Amplification for AD and PD Biomarkers

    July 10, 2026

    We are pleased to share our latest research paper, “Analysis of Single Particles ...

  • attyloid to showcase biomarkers across pathology and biology at AD/PD™ 2026 conference

    March 3, 2026